=== PAGE 7 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
James H. Medley
Althera Pharmaceuticals LLC
NDA 213072 MA 4

Page 7

correspondence relating to this particular matter. All correspondence should include a
subject line that clearly identifies the submission as a Response to Untitled Letter. You are
encouraged, but not required, to submit your response in eCTD format. All correspondence
submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.
Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 0044 under NDA 213072. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.

                                            Sincerely,

                                            {See appended electronic signature page}

                                            Ankur Kalola, PharmD, RAC
                                            Regulatory Review Officer
                                            Division of Advertising & Promotion Review 2
                                            Office of Prescription Drug Promotion


                                            {See appended electronic signature page}

                                            Melinda Wilson, PharmD, MPH, BCPS,
                                            RAC
                                            Team Leader
                                            Division of Advertising & Promotion Review 2
                                            Office of Prescription Drug Promotion

Reference ID: 4993452
